158 related articles for article (PubMed ID: 6174453)
1. Metabolic and synthetic activities of Pneumocystis carinii in vitro.
Pesanti EL; Cox C
Infect Immun; 1981 Dec; 34(3):908-14. PubMed ID: 6174453
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of antiprotozoan drugs and immune serum on Pneumocystis carinii.
Pesanti EL
J Infect Dis; 1980 Jun; 141(6):775-80. PubMed ID: 6156221
[TBL] [Abstract][Full Text] [Related]
3. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.
Cushion MT; Stanforth D; Linke MJ; Walzer PD
Antimicrob Agents Chemother; 1985 Dec; 28(6):796-801. PubMed ID: 3936409
[TBL] [Abstract][Full Text] [Related]
4. Biological profile and response to anti-pneumocystis agents of Pneumocystis carinii in cell culture.
Pifer LL; Pifer DD; Woods DR
Antimicrob Agents Chemother; 1983 Nov; 24(5):674-8. PubMed ID: 6607029
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of Pneumocystis carinii in culture.
Bartlett MS; Eichholtz R; Smith JW
Diagn Microbiol Infect Dis; 1985 Sep; 3(5):381-7. PubMed ID: 3875445
[TBL] [Abstract][Full Text] [Related]
6. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
[TBL] [Abstract][Full Text] [Related]
7. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Kovacs JA; Allegra CJ; Beaver J; Boarman D; Lewis M; Parrillo JE; Chabner B; Masur H
J Infect Dis; 1989 Aug; 160(2):312-20. PubMed ID: 2527275
[TBL] [Abstract][Full Text] [Related]
8. Polyamine metabolism in Pneumocystis carinii.
Lipschik GY; Masur H; Kovacs JA
J Infect Dis; 1991 May; 163(5):1121-7. PubMed ID: 2019760
[TBL] [Abstract][Full Text] [Related]
9. Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats.
Kluge RM; Spaulding DM; Spain AJ
Antimicrob Agents Chemother; 1978 Jun; 13(6):975-8. PubMed ID: 307941
[TBL] [Abstract][Full Text] [Related]
10. Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.
Comley JC; Mullin RJ; Wolfe LA; Hanlon MH; Ferone R
Antimicrob Agents Chemother; 1991 Oct; 35(10):1965-74. PubMed ID: 1759815
[TBL] [Abstract][Full Text] [Related]
11. Growth and metabolism of Pneumocystis carinii in axenic culture.
Dis Markers; 1991; 9(1):55. PubMed ID: 1742950
[No Abstract] [Full Text] [Related]
12. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.
Cushion MT; Collins M; Hazra B; Kaneshiro ES
Antimicrob Agents Chemother; 2000 Mar; 44(3):713-9. PubMed ID: 10681344
[TBL] [Abstract][Full Text] [Related]
13. Detection of two distinct transporter systems for 2-deoxyglucose uptake by the opportunistic pathogen Pneumocystis carinii.
Basselin-Eiweida M; Kaneshiro ES
Biochim Biophys Acta; 2001 Dec; 1515(2):177-88. PubMed ID: 11718673
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of amino acid and glucose uptake by Pneumocystis carinii.
Basselin-Eiweida M; Qiu YH; Lipscomb KJ; Kaneshiro ES
J Eukaryot Microbiol; 2001; Suppl():155S-156S. PubMed ID: 11906039
[No Abstract] [Full Text] [Related]
15. Enhanced efficacy of a liposomal pentamidine preparation in Pneumocystis carinii in an ex vivo/in vitro culture model without feederlayer cells.
Sahm M; Wingen F; Hager J; Seitz HM
Appl Parasitol; 1996 Jun; 37(2):137-45. PubMed ID: 8688862
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of in vitro splicing of a group I intron of Pneumocystis carinii.
Liu Y; Tidwell RR; Leibowitz MJ
J Eukaryot Microbiol; 1994; 41(1):31-8. PubMed ID: 8124264
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.
Hughes WT; McNabb PC; Makres TD; Feldman S
Antimicrob Agents Chemother; 1974 Mar; 5(3):289-93. PubMed ID: 4365115
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis carinii: oxygen uptake, antioxidant enzymes, and susceptibility to oxygen-mediated damage.
Pesanti EL
Infect Immun; 1984 Apr; 44(1):7-11. PubMed ID: 6323317
[TBL] [Abstract][Full Text] [Related]
20. Pteroylpolyglutamate synthesis by lung- and culture-derived Pneumocystis carinii.
Hong YL; Bartlett MS; Queener S; Smith JW; Shaw M; Meshnick SR
FEMS Microbiol Lett; 1995 Dec; 134(2-3):251-4. PubMed ID: 8586276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
